What did we learn from ‘omics’ studies in osteoarthritis : Current Opinion in Rheumatology

Secondary Logo

Journal Logo

OSTEOARTHRITIS: Edited by Mukundan Attur

What did we learn from ‘omics’ studies in osteoarthritis

Ruiz-Romero, Cristina; Rego-Perez, Ignacio; Blanco, Francisco J.

Author Information
Current Opinion in Rheumatology 30(1):p 114-120, January 2018. | DOI: 10.1097/BOR.0000000000000460


Purpose of review 

‘Omics’ technologies developed for the massive analysis of the major biologically relevant molecules (genes, proteins, metabolites) have been applied to the study of osteoarthritis (OA) for more than a decade.

Recent findings 

‘Omics’ studies have undoubtedly contributed to increase the knowledge on pathogenic processes related with OA and have provided hundreds to thousands of molecules that might have a putative biomarker utility for this disease.


This review describes the most recent ‘omics’ studies in OA research, their conclusions, and discuss those remaining challenges. Still many validation studies must be performed in large and well-characterized cohorts for the translation of the findings from ‘omics’ strategies to clinical applications. The development of tools for the intelligent integration of ‘omics’ data with clinical and imaging information is also mandatory to take full profit of the work that has been already performed.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid